Versanis Bio

Part of Eli Lilly and Company

Company

Versanis Bio develops one asset, in phase 3 (bimagrumab in sporadic inclusion body myositis). Mostly antibody acting on ACVR2B.

1
Asset
Furthest stage
Phase 3
0
Trials
5
Signals

Pipeline

1
  • bimagrumab

    Blocks activin type II receptors, promoting muscle growth and reducing fat mass.

    Phase 3, Antibody, ACVR2B, sporadic inclusion body myositis, sarcopenia (Phase 2), Partner

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials1
  • Signals20
  • Similar companies6

Intelligence